RecruitingPhase 3NCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Studying Fibrosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Day One Biopharmaceuticals, Inc.
Intervention
Tovorafenib(drug)
Enrollment
400 enrolled
Eligibility
25 years · All sexes
Timeline
20232031

Study locations (30)

Collaborators

SIOPe Brain Tumor Group LOGGIC Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05566795 on ClinicalTrials.gov

Other trials for Fibrosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrosarcoma

← Back to all trials